Cyclacel Pharmaceuticals Inc (CYCC)
2.48
-0.20
(-7.47%)
USD |
NASDAQ |
May 02, 16:00
2.26
-0.22
(-8.87%)
After-Hours: 20:00
Cyclacel Pharmaceuticals Accounts Payable (Quarterly): 3.543M for Dec. 31, 2023
Accounts Payable (Quarterly) Chart
Historical Accounts Payable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 3.543M |
September 30, 2023 | 1.571M |
June 30, 2023 | 2.169M |
March 31, 2023 | 2.509M |
December 31, 2022 | 2.561M |
September 30, 2022 | 0.983M |
June 30, 2022 | 2.205M |
March 31, 2022 | 2.85M |
December 31, 2021 | 2.117M |
September 30, 2021 | 1.515M |
June 30, 2021 | 1.197M |
March 31, 2021 | 0.871M |
December 31, 2020 | 0.514M |
September 30, 2020 | 0.455M |
June 30, 2020 | 0.342M |
March 31, 2020 | 0.25M |
December 31, 2019 | 0.89M |
September 30, 2019 | 0.887M |
June 30, 2019 | 1.106M |
March 31, 2019 | 1.284M |
December 31, 2018 | 2.719M |
September 30, 2018 | 1.411M |
June 30, 2018 | 1.675M |
March 31, 2018 | 1.949M |
December 31, 2017 | 1.558M |
Date | Value |
---|---|
September 30, 2017 | 1.973M |
June 30, 2017 | 2.038M |
March 31, 2017 | 1.652M |
December 31, 2016 | 2.497M |
September 30, 2016 | 1.979M |
June 30, 2016 | 1.898M |
March 31, 2016 | 1.582M |
December 31, 2015 | 1.94M |
September 30, 2015 | 1.616M |
June 30, 2015 | 2.609M |
March 31, 2015 | 4.007M |
December 31, 2014 | 2.792M |
September 30, 2014 | 2.201M |
June 30, 2014 | 4.543M |
March 31, 2014 | 4.719M |
December 31, 2013 | 2.545M |
September 30, 2013 | 2.352M |
June 30, 2013 | 2.437M |
March 31, 2013 | 2.825M |
December 31, 2012 | 2.259M |
September 30, 2012 | 1.642M |
June 30, 2012 | 1.544M |
March 31, 2012 | 1.116M |
December 31, 2011 | 1.717M |
September 30, 2011 | 1.101M |
Accounts Payable Definition
Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.
Accounts Payable (Quarterly) Range, Past 5 Years
0.25M
Minimum
Mar 2020
3.543M
Maximum
Dec 2023
1.502M
Average
1.197M
Median
Jun 2021
Accounts Payable (Quarterly) Benchmarks
Corvus Pharmaceuticals Inc | 1.525M |
Oragenics Inc | 1.245M |
Relmada Therapeutics Inc | 3.506M |
Alpine Immune Sciences Inc | 3.593M |
MAIA Biotechnology Inc | 1.638M |